Citi analyst David Lebowitz lowered the firm’s price target on 23andMe to 47c from 85c and keeps a Neutral rating on the shares. Last week, 23andMe presented data on two in-house immunotherapies 23ME-001473 and 23ME-00610, at the American Association for Cancer Research, the analyst tells investors in a research note. Separately, the firm says the shares remain out of compliance with Nasdaq rules requiring the stock price to be over $1.00, threatening its listing on the exchange. It believes the full financial impact from ongoing class action claims related to the company’s data theft remains unclear.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ME:
- WW appoints new executive leaders
- 23andMe to Present Data on Two Clinical Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024
- 23andMe CAO Kathy Hibbs Retires, Guy Chayoun Steps In
- 23andMe initiates Phase 1 trial for 23ME-01473
- 23andMe Initiates Phase 1 Clinical Trial for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6